Nektar Therapeutics Stock Drops Amid Jury Deliberation in Dispute with Eli Lilly
Nektar Therapeutics (NKTR) experienced an 11% decline as a federal court jury deliberated on its legal dispute with Eli Lilly over the Rezpeg drug. The case, ongoing since Friday, centers around intellectual property and commercial rights related to the medication. Market reactions suggest investor concern about potential adverse outcomes from the litigation. The stock's sharp drop highlights sensitivity in biotech markets toward high-stakes patent disputes that can significantly affect revenue streams or market exclusivity for key products. The outcome of this case could influence Nektar’s financial stability and strategic direction, particularly if a ruling favors Eli Lilly (LLY).
Topics: lawsuit pharmaceuticals stock_movement